Related Experiment Videos
[Aspergillus lung pathology in transplant patients]
1Division des Maladies Infectieuses, Hôpital Cantonal Universitaire, Genève, Suisse.
Revue Des Maladies Respiratoires
|November 1, 1996
Summary
Invasive pulmonary aspergillosis is a severe post-transplant complication influenced by transplant type and immunosuppression. Early diagnosis and effective antifungal treatment, such as amphotericin B or itraconazole, are crucial for patient outcomes.
Area of Science:
- Medical Mycology
- Transplant Infectious Diseases
- Pulmonology
Context:
- Invasive pulmonary aspergillosis (IPA) is a serious complication following organ transplantation.
- Incidence varies with transplant type, immunosuppression intensity, and hospital environment (e.g., air conditioning, renovations).
- Early detection and management are critical for improving patient survival rates.
Purpose:
- To review the epidemiology, clinical presentation, diagnostic challenges, and therapeutic options for invasive pulmonary aspergillosis in transplant recipients.
- To highlight the importance of environmental factors and diagnostic advancements.
- To discuss current and emerging antifungal treatment strategies.
Summary:
- IPA presents with nonspecific symptoms like persistent fever, often requiring advanced imaging (CT, MRI) for diagnosis.
- Bronchoalveolar lavage sensitivity is low; future diagnostics may involve Aspergillus DNA amplification and antigen detection.
- Intravenous amphotericin B remains the primary treatment, with lipid formulations as alternatives. Itraconazole shows promise due to fewer side effects.
Impact:
- Improved understanding of IPA risk factors and diagnostic limitations in transplant patients.
- Informed clinical decision-making regarding diagnostic workup and antifungal therapy selection.
- Highlights the need for further research into standardized diagnostic tests and optimized antifungal formulations.